Jiankai D. Liang
Guangzhou, 510080, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Retraction Note: DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage.
Journal: Nature communications
Published: October 24, 2025
Identification of YBX1 as an essential host RNA-binding protein governing tumor-selective replication of oncolytic virus M1.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: September 21, 2025
Advances in the treatment of anaplastic thyroid carcinoma
Journal: Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Published: August 24, 2025
Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: June 10, 2025
HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma.
Journal: Frontiers in immunology
Published: May 05, 2025
Reduced oxytocin signaling in the dBNST drives the transition from acute pain to persistent anxiety.
Reduced oxytocin signaling in the dBNST drives the transition from acute pain to persistent anxiety.
Journal: Current biology : CB
Published: April 08, 2025
circ-1584 selectively promotes the antitumor activity of the oncolytic virus M1 on pancreatic cancer.
Journal: Molecular therapy. Oncology
Published: June 24, 2024
Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation.
Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8+ T cell activation.
Journal: Molecular therapy. Oncology
Published: March 12, 2024
Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway.
Journal: Acta pharmaceutica Sinica. B
Published: October 23, 2023
Last Updated: 09/26/2026